- Home
- BEAG vs CMPX Comparison
BEAG vs CMPX Comparison
Compare BEAG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAG
- CMPX
- Stock Information
- Founded
- BEAG 2021
- CMPX 2014
- Country
- BEAG United States
- CMPX United States
- Employees
- BEAG N/A
- CMPX N/A
- Industry
- BEAG
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- BEAG
- CMPX Health Care
- Exchange
- BEAG NYSE
- CMPX Nasdaq
- Market Cap
- BEAG 326.6M
- CMPX 291.8M
- IPO Year
- BEAG 2024
- CMPX N/A
- Fundamental
- Price
- BEAG $10.47
- CMPX $3.18
- Analyst Decision
- BEAG
- CMPX Strong Buy
- Analyst Count
- BEAG 0
- CMPX 9
- Target Price
- BEAG N/A
- CMPX $12.67
- AVG Volume (30 Days)
- BEAG 154.5K
- CMPX 867.7K
- Earning Date
- BEAG 01-01-0001
- CMPX 08-11-2025
- Dividend Yield
- BEAG N/A
- CMPX N/A
- EPS Growth
- BEAG 221.31
- CMPX N/A
- EPS
- BEAG 0.28
- CMPX N/A
- Revenue
- BEAG N/A
- CMPX $850,000.00
- Revenue This Year
- BEAG N/A
- CMPX N/A
- Revenue Next Year
- BEAG N/A
- CMPX N/A
- P/E Ratio
- BEAG $37.37
- CMPX N/A
- Revenue Growth
- BEAG N/A
- CMPX N/A
- 52 Week Low
- BEAG $9.84
- CMPX $0.87
- 52 Week High
- BEAG $11.20
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- BEAG N/A
- CMPX 63.96
- Support Level
- BEAG N/A
- CMPX $2.96
- Resistance Level
- BEAG N/A
- CMPX $3.45
- Average True Range (ATR)
- BEAG 0.00
- CMPX 0.20
- MACD
- BEAG 0.00
- CMPX 0.02
- Stochastic Oscillator
- BEAG 0.00
- CMPX 67.47
About BEAG BOLD EAGLE ACQUISITION CORP
Bold Eagle Acquisition Corp is a blank check company.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.